CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Catherine C. Coombs, John M. Pagel, Nirav N. Shah, Nicole Lamanna, Talha Munir, Ewa Lech-Maranda, Toby A. Eyre, Jennifer A. Woyach, William G. Wierda, Chan Y. Cheah, Jonathon B. Cohen, Lindsey E. Roeker, Manish R. Patel, Bita Fakhri, Minal A. Barve, Constantine S. Tam, David Lewis, James N. Gerson, Alvaro Alencar, Chaitra UjjaniIan Flinn, Suchitra Sundaram, Shuo Ma, Deepa Jagadeesh, Joanna Rhodes, Justin Taylor, Omar Abdel-Wahab, Paolo Ghia, Stephen J. Schuster, Denise Wang, Binoj Nair, Edward Zhu, Donald E. Tsai, Matthew S. Davids, Jennifer R. Brown, Wojciech Jurczak, Anthony R. Mato

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study'. Together they form a unique fingerprint.

Medicine & Life Sciences